Examinando por Autor "Orellana, Paulina"

Mostrando 1 - 2 de 2
  • No hay miniatura disponible
    Ítem
    Biomarkers for dementia in Latin American countries: Gaps and opportunities
    (John Wiley and Sons Inc, 2023-02) Parra, Mario A.; Orellana, Paulina; Leon, Tomas; Victoria, Cabello G.; Henriquez, Fernando; Gomez, Rodrigo; Avalos, Constanza; Damian, Andres; Slachevsky, Andrea; Ibañez, Agustin; Zetterberg, Henrik; Tijms, Betty M.; Yokoyama, Jennifer S.; Piña-Escudero, Stefanie D.; Cochran, J. Nicholas; Matallana, Diana L.; Acosta, Daisy; Allegri, Ricardo; Arias-Suárez, Bianca P.; Barra, Bernardo; Behrens, Maria Isabel; Brucki, Sonia M. D.; Busatto, Geraldo; Caramelli, Paulo; Castro-Suarez, Sheila; Contreras, Valeria; Custodio, Nilton; Dansilio, Sergio; la Cruz-Puebla, Myriam De; de Souza, Leonardo Cruz; Diaz, Monica M.; Duque, Lissette; Farías, Gonzalo A.; Ferreira, Sergio T.; Guimet, Nahuel Magrath; Kmaid, Ana; Lira, David; Lopera, Francisco; Meza, Beatriz Mar; Miotto, Eliane C.; Nitrini, Ricardo; Nuñez, Alberto; O'Neill, Santiago; Ochoa, John; Pintado-Caipa, Maritza; Resende, Elisa de Paula França; Risacher, Shannon; Rojas, Luz Angela; Sabaj, Valentina; Schilling, Lucas; Sellek, Allis F.; Sosa, Ana; Takada, Leonel T.; Teixeira, Antonio L.; Unaucho-Pilalumbo, Martha; Duran-Aniotz, Claudia
    Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts. © 2022 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
  • Miniatura
    Ítem
    Differential expression profile of CXCR3 splicing variants is associated with thyroid neoplasia. Potential role in papillary thyroid carcinoma oncogenesis?
    (Impact Journals LLC, 2018) Gamboa, Soledad Urra; Fischer, Martin C.; Martínez, José R.; Véliz, Loreto; Orellana, Paulina; Solar, Antonieta; Bohmwald, Karen; Kalergis, Alexis; Riedel, Claudia; Corvalán, Alejandro H.; Roa, Juan C.; Fuentealba, Rodrigo; Cáceres, C. Joaquín; López-Lastra, Marcelo; León, Augusto; Droppelmann, Nicolás; González, Hernán E.
    Papillary thyroid cancer (PTC) is the most prevalent endocrine neoplasia. The increased incidence of PTC in patients with thyroiditis and the frequent immune infiltrate found in PTC suggest that inflammation might be a risk factor for PTC development. The CXCR3-ligand system is involved in thyroid inflammation and CXCR3 has been found upregulated in many tumors, suggesting its pro-tumorigenic role under the inflammatory microenvironment. CXCR3 ligands (CXCL4, CXCL9, CXCL10 and CXCL11) trigger antagonistic responses partly due to the presence of two splice variants, CXCR3A and CXCR3B. Whereas CXCR3A promotes cell proliferation, CXCR3B induces apoptosis. However, the relation between CXCR3 variant expression with chronic inflammation and PTC development remains unknown. Here, we characterized the expression pattern of CXCR3 variants and their ligands in benign tumors and PTC. We found that CXCR3A and CXCL10 mRNA levels were increased in non-metastatic PTC when compared to non-neoplastic tissue. This increment was also observed in a PTC epithelial cell line (TPC-1). Although elevated protein levels of both isoforms were detected in benign and malignant tumors, the CXCR3A expression remained greater than CXCR3B and promoted proliferation in Nthy-ori-3-1 cells. In non-metastatic PTC, inflammation was conditioning for the CXCR3 ligands increased availability. Consistently, CXCL10 was strongly induced by interferon gamma in normal and tumor thyrocytes. Our results suggest that persistent inflammation upregulates CXCL10 expression favoring tumor development via enhanced CXCR3A-CXCL10 signaling. These findings may help to further understand the contribution of inflammation as a risk factor in PTC development and set the basis for potential therapeutic studies.